• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

    9/27/21 6:00:00 AM ET
    $ASLN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASLN alert in real time by email

    - Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile

    - ASLAN004 achieved a statistically significant improvement (p<0.0251) versus placebo in the primary efficacy endpoint of percent change from baseline in EASI with significant improvements in other efficacy endpoints



    - Well-tolerated with no cases of conjunctivitis in the expansion cohort



    - On track to enroll first patient in global Phase 2b study in 4Q 21



    - Management to host conference call and webcast today, 27 September, at 8am ET / 8pm SGT



    MENLO PARK, Calif. and SINGAPORE, Sept. 27, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced positive topline data from its randomized, double-blind, placebo-controlled, 8-week, multiple-ascending-dose (MAD) Phase 1 study of ASLAN004 for the treatment of moderate-to-severe atopic dermatitis (AD). ASLAN004, a potential first-in-class monoclonal antibody that targets the IL-13 receptor, was shown to be well tolerated across all doses. Data from the study conclusively establishes proof of concept, and supports the potential of ASLAN004 as a differentiated, novel treatment for AD.

    In March 2021, ASLAN announced interim data from three dose escalation cohorts, then continued to enroll and treat an additional 27 patients in an expansion cohort at the highest dose (600mg). The results announced today compare results from all patients receiving 600mg to all receiving placebo (n=39). The Intent to Treat (ITT) population (n=38) comprised patients from 10 sites and represented all patients dosed excluding one patient that discontinued from the study prematurely due to COVID-19 restrictions.

    ASLAN004 achieved a statistically significant improvement (p<0.0251) versus placebo in the primary efficacy endpoint of percent change from baseline in the Eczema Area Severity Index (EASI), and also showed significant improvements (p<0.051) in other key efficacy endpoints: EASI-50, EASI-75, peak pruritus and the Patient-Oriented Eczema Measure (POEM).

    Following discussions with the Data Monitoring Committee prior to unblinding, a Revised ITT population (RITT, n=29) was defined to exclude one study site at which all patients enrolled in the study appeared atypical of moderate-to-severe AD patients based on biomarkers, such as TARC, and patient medical history2. In the RITT population, which is more comparable to other published studies3 in moderate-to-severe AD, ASLAN004 also achieved a statistically significant improvement (p<0.0251) versus placebo in percent change from baseline in EASI and showed a greater improvement over placebo in the key efficacy endpoints versus the ITT population.

    Key study results

    • In the RITT population, the average reduction from baseline in EASI at 8 weeks was 65% (n=16) compared to 27% (n=13) for patients on placebo (p=0.0211). 
      • 69% achieved EASI-75 versus 15% on placebo (p=0.0051); 
      • 44% of patients achieved Investigator's Global Assessment (IGA) of 0 or 1 versus 15% on placebo (p=0.1071).
    • In the 32 patients that completed at least 29 days of dosing across all sites, defined in the protocol as the efficacy evaluable data set, the average reduction from baseline in EASI at 8 weeks was 73% (n=19) compared to 44% (n=13) for patients on placebo (p=0.0071).
    • The proportion of patients with adverse events and treatment-related adverse events were similar across treatment and placebo arms. There were no incidences of conjunctivitis in the expansion cohort. 



    Endpoint (8 weeks)



    RITT (n=29)ITT (n=38)
    600mg

    (n=16)
    Placebo

    (n=13)
    p-value1600mg

    (n=22)
    Placebo

    (n=16)
    p-value1
    Mean % change from baseline in EASI-64.9-27.20.021-61.3-31.90.023
    EASI-50 (%)81.330.80.00877.337.50.016
    EASI-75 (%)68.815.40.00550.012.50.018
    EASI-90 (%)37.515.40.18327.312.50.245
    IGA 0/1 (%)43.815.40.10731.818.80.301
    Mean % change from baseline in peak pruritus

    Numerical Rating Scale
    -38.6-15.30.051-37.1-15.70.032
    Mean change from baseline in POEM-9.8-2.50.007-9.0-3.50.014

    Dr Ken Kobayashi, Chief Medical Officer, ASLAN Pharmaceuticals, commented: "We're delighted to report such positive data on ASLAN004. The data from the study wholly support our view that ASLAN004's novel mechanism could represent a new treatment option for patients suffering with moderate-to-severe AD, with the potential to deliver best-in-class efficacy and best-in-class safety. We look forward to building upon this strong data set as we initiate the Phase 2b study in the coming weeks and explore monthly dosing regimens that could provide additional convenience to patients."

    Dr Steven Thng, Principal Investigator, said: "Atopic dermatitis is one of the most common dermatological diseases worldwide and presents with a range of symptoms that have a tremendous negative impact on a patient's quality of life. Patients, especially those with moderate-to-severe disease, are still in great need of novel treatment options that are safe, efficacious and convenient to use to overcome the limitations of options currently available to them. The findings from the study show the potential benefit that ASLAN004 could offer patients in achieving almost completely clear skin and relief from the burden of atopic dermatitis on daily life."

    ASLAN is initiating a global Phase 2b study of ASLAN004 for the treatment of AD and is on track to enroll the first patient in 4Q 2021. ASLAN will host a KOL event on ASLAN004 in AD for investors in 4Q 2021. The full data from the MAD study will be submitted for presentation at a future scientific congress.

    Conference call and webcast 

    ASLAN's management will host a webcast and conference call at 8am ET today, September 27, 2021, to discuss these data. The live webcast may be accessed in listen-only mode via http://public.viavid.com/index.php?id=146567 or via the company's website at https://ir.aslanpharma.com/webcasts-presentations. For audio access dial +1 877-407-3982 for US callers and +1 201 493 6780 for international callers and enter the conference code: 13723237.



    A replay of the call and webcast will be archived using the information above immediately after the live event.

    Media and IR contacts

    Emma Thompson

    Spurwing Communications

    Tel: +65 6206 7350

    Email: [email protected]

    Ashley R. Robinson

    LifeSci Advisors, LLC

    Tel: +1 (617) 430-7577

    Email: [email protected]

    About ASLAN Pharmaceuticals

    ASLAN Pharmaceuticals (NASDAQ:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information, please visit www.aslanpharma.com or follow ASLAN on LinkedIn.



    About ASLAN004 

    ASLAN004 is a novel, potential first-in-class monoclonal antibody that targets the IL-13 receptor α1 subunit

    (IL-13Rα1), a component of the Type 2 receptor. By blocking the Type 2 receptor, ASLAN004 prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13), the key drivers of inflammation, central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin, and in other atopic disease. We believe that this unique action of blocking the IL-13 receptor rather than the IL-4 receptor has the potential for improved efficacy, safety and dose regimen. ASLAN004 is the only IL-13Rα1 inhibitor in clinical development for the treatment of AD.

    About the study 

    The Phase 1 study was a multiple ascending dose study designed to deliver proof of concept and evaluated three doses of ASLAN004 (200mg, 400mg and 600mg) delivered subcutaneously compared to a placebo arm. Patients were dosed weekly for eight weeks to determine the safety and tolerability of ASLAN004, and to assess a number of secondary efficacy outcome measures. In total, 53 patients were randomized in the MAD study from 10 sites in the United States, Australia and Singapore.

    Forward-looking statements

    This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company's business strategy and clinical development plans; the Company's plans to develop and commercialize ASLAN004; the safety and efficacy of ASLAN004, including its potential to be best-in-class; the Company's plans and expected timing with respect to clinical trials, clinical trial enrolment and clinical trial results for ASLAN004; and the potential for ASLAN004 as a first-in-class treatment for atopic dermatitis. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic on the Company's business and the global economy; general market conditions; changes in the competitive landscape; and the Company's ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company's US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Annual Report on Form 20-F filed with the US Securities and Exchange Commission on April 23, 2021. All statements other than statements of historical fact are forward-looking statements. The words "believe," "view," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.

    __________________________

    1 One-sided p-value. Study was powered to assess statistical significance in the primary efficacy endpoint at the one-sided 5% level.

    2 The average level of TARC, a biomarker that correlates with AD severity, in the RITT was 4,652 pg/ml (compared to 461 pg/ml at the site excluded from the RITT), in line with previous published clinical studies3 in moderate-to-severe AD, which had average TARC levels between 4,832 and 6,230 pg/ml. Only one out of nine patients at the excluded site had allergic co-morbidities compared to 87% in other sites. Other measures, such as eosinophils and enzyme LDH were also atypical of moderate-to-severe AD.

    3 Beck et al (2014) N Engl J Med 371:130. Hamilton et al (2019), 49th Annual ESDR Meeting Sep 18-21, 2019



    Primary Logo

    Get the next $ASLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASLN

    DatePrice TargetRatingAnalyst
    7/9/2021$8.00Buy
    Jefferies
    More analyst ratings

    $ASLN
    Leadership Updates

    Live Leadership Updates

    See more
    • ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

      New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrationsLeading respiratory experts, Ramaswamy Krishnan, PhD, and Reynold Panettieri, MD, appointed as scientific advisors to provide strategic counsel on eblasakimab's differentiation for future clinical development in COPD SAN MATEO, Calif. and SINGAPORE, March 06, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (NASDAQ:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of p

      3/6/24 7:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer

      - Dermatologist with over twenty years of experience in senior biopharma roles in the US and Europe, including positions at Almirall, Allergan and Novartis- Strengthens leadership team as eblasakimab (also known as ASLAN004) moves into late-stage trials MENLO PARK, Calif. and SINGAPORE, March 15, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Alex Kaoukhov, MD, as Chief Medical Officer based in ASLAN's US office, effective immediately. Alex was most recently Head of Clinical Development, Senior Vice President

      3/15/22 7:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration

      MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials, including the global oversight, expansion and engagement of patients for trials related to the clinical development of ASLAN004 and ASLAN003. IQVIA Biotech will provide pati

      12/6/21 7:00:00 AM ET
      $ASLN
      $IQV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch

    $ASLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

      SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      3/21/24 4:42:13 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

      SC 13G - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      3/19/24 4:30:30 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ASLAN Pharmaceuticals Limited (Amendment)

      SC 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      2/14/24 4:45:26 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on ASLAN Pharmaceuticals with a new price target

      Jefferies initiated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00

      7/9/21 7:45:23 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on ASLAN Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00 from $5.00 previously

      3/17/21 6:40:11 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    SEC Filings

    See more
    • SEC Form 25-NSE filed by ASLAN Pharmaceuticals Limited

      25-NSE - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      9/6/24 7:41:52 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ASLAN Pharmaceuticals Limited

      SCHEDULE 13G/A - ASLAN Pharmaceuticals Ltd (0001722926) (Subject)

      8/8/24 11:36:38 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ASLAN Pharmaceuticals Limited

      6-K - ASLAN Pharmaceuticals Ltd (0001722926) (Filer)

      7/17/24 7:29:55 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ASLN
    Financials

    Live finance-specific insights

    See more
    • ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation

      Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore) Pte Limited International has been appointed as the official liquidator and will seek potential strategic alternatives for the Company's development programs, eblasakimab and farudodstat SAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals ("ASLAN" or the "Company"), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that its Singapore-incorporated, sole oper

      7/17/24 7:25:04 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal

      SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that on July 9, 2024, the Company was notified by the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company's non-compliance with the $1.00 bid price and $2.5 million stockholders' equity requirements for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively, the Staff

      7/15/24 7:30:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

      SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares ("ADSs") to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares. For the Company's existing ADS holders, the change in the ADS ratio will have the same effect as a one-for-eight reverse ADS split. There will be no change to the C

      6/14/24 4:54:19 PM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

      - Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p<0.0251) versus placebo in the primary efficacy endpoint of percent change from baseline in EASI with significant improvements in other efficacy endpoints- Well-tolerated with no cases of conjunctivitis in the expansion cohort- On track to enroll first patient in global Phase 2b study in 4Q 21- Management to host conference call and webcast today, 27 September, at 8am ET / 8pm SGTMENLO PARK, Calif. and SINGAPORE, Sept. 27, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology

      9/27/21 6:00:00 AM ET
      $ASLN
      Biotechnology: Pharmaceutical Preparations
      Health Care